加味丹参饮联合西药治疗冠心病心绞痛心血瘀阻型的疗效观察
|
摘要
目的:探讨加味丹参饮联合西药治疗冠心病心绞痛心血瘀阻型的临床疗效与可行性。方法:选取2017年7月-2018年8月我院综合内科收治的78例冠心病心绞痛心血瘀阻型患者,随机分为观察组39例与对照组39例,对照组口服西药阿司匹林肠溶片+单硝酸异山梨酯缓释片+酒石酸美托洛尔片,心绞痛发作时舌下含服硝酸甘油,观察组在此基础上给予加味丹参饮,比较两组临床疗效、治疗前后心绞痛发作、硝酸甘油停减率与药物不良反应情况。结果:观察组治疗总有效率为92.31%,对照组总有效率为74.36%,两组比较,差异有统计学意义(P <0.05);治疗后观察组心绞痛发作次数较对照组明显减少,差异有统计学意义(P <0.05),且观察组硝酸甘油停减率达84.62%,明显高于对照组的58.97%,差异有统计学意义(P <0.05)。两组均出现轻度不良反应,经对症处理后症状消失,不良反应发生率比较,差异无统计学意义(P> 0.05)。结论:加味丹参饮联合西药治疗冠心病心绞痛心血瘀阻型效果优于单一西药治疗,而且不会增加不良反应,安全性较高,值得临床推广应用。
Objective: To investigate the clinical feasibility and efficacy of Danshen Yin( 丹参饮) and western medicine on angina pectoris of the Xinxue Yuzu type( 心血瘀阻型). Methods: 78 patients were randomly divided into the observation group and the control group, 39 cases in each. The control group was treated with aspirin enteric tablets, isosorbide mononitrate sustained release tablets and metoprolol tartrate tablets, and given nitroglycerin under the tongue during angina attacks. The observation group was given Danshen Yin more. The clinical efficacy, angina pectoris before and after treatment, nitroglycerin withdrawal rate and adverse reactions in two groups were compared. Results: The total efficiency in the observation group was 92.31%, and was 74.36% in the control group, with a statistically significant difference(P<0.05). The number of angina attacks in the observation group was significantly lower than the control group, with a statistically significant difference(P<0.05). The nitroglycerin withdrawal rate was 84.62% in the observation group, significantly higher than 58.97% in the control group, with a statistically significant difference(P<0.05). There were mild adverse reactions in both groups,The symptoms were disappeared after symptomatic treatment. There was no statistically significant difference in the incidence of adverse reactions(P>0.05). Conclusion: Danshen Yin plus western medicine shows a better effect, did not increase adverse reactions, with high safety, and is worthy of clinical application.
Objective: To investigate the clinical feasibility and efficacy of Danshen Yin( 丹参饮) and western medicine on angina pectoris of the Xinxue Yuzu type( 心血瘀阻型). Methods: 78 patients were randomly divided into the observation group and the control group, 39 cases in each. The control group was treated with aspirin enteric tablets, isosorbide mononitrate sustained release tablets and metoprolol tartrate tablets, and given nitroglycerin under the tongue during angina attacks. The observation group was given Danshen Yin more. The clinical efficacy, angina pectoris before and after treatment, nitroglycerin withdrawal rate and adverse reactions in two groups were compared. Results: The total efficiency in the observation group was 92.31%, and was 74.36% in the control group, with a statistically significant difference(P<0.05). The number of angina attacks in the observation group was significantly lower than the control group, with a statistically significant difference(P<0.05). The nitroglycerin withdrawal rate was 84.62% in the observation group, significantly higher than 58.97% in the control group, with a statistically significant difference(P<0.05). There were mild adverse reactions in both groups,The symptoms were disappeared after symptomatic treatment. There was no statistically significant difference in the incidence of adverse reactions(P>0.05). Conclusion: Danshen Yin plus western medicine shows a better effect, did not increase adverse reactions, with high safety, and is worthy of clinical application.
引文
[1]唐梅森,黄政德,向忠军,等.加味丹参饮联合西药治疗冠心病心绞痛心血瘀阻证68例疗效观察[J].中医杂志,2015,56(5):395-397.
[2]熊琴梅,周琼琼,刘勇,等.冠心病患者生活质量现状及其相关影响因素分析[J].临床心血管病杂志,2014,30(1):27-30.
[3]何庆勇,王阶,姚魁武,等.以证候要素为内容的冠心病心绞痛中医疗效评价体系研究[J].中华中医药杂志,2014,29(12):3809-3814.
[4]石亚飞,闫荟,孙世光,等.两种丹参类中药注射剂治疗冠心病心绞痛的系统评价及其药物经济学分析[J].中国循证医学杂志,2014,14(3):287-291.
[5]熊周勇,周燕弟.加味丹参饮联合西药治疗冠心病心绞痛心血瘀阻证的临床观察[J].光明中医,2017,32(18):2688-2690.
[6]金香兰.加味丹参饮联合西药治疗冠心病心绞痛心血瘀阻证35例疗效分析[J].中国实用医药,2016,11(25):181-182.
[7]毕颖斐,毛静远,王贤良,等.中医药防治冠心病临床优势及有关疗效评价的思考[J].中医杂志,2015,56(5):437-440.
[8]殷佳,宋彦奇,潘晔,等.基于临床文献探讨冠心病气阴两虚证动物模型的评价标准[J].中草药,2017,48(4):798-802.
[2]熊琴梅,周琼琼,刘勇,等.冠心病患者生活质量现状及其相关影响因素分析[J].临床心血管病杂志,2014,30(1):27-30.
[3]何庆勇,王阶,姚魁武,等.以证候要素为内容的冠心病心绞痛中医疗效评价体系研究[J].中华中医药杂志,2014,29(12):3809-3814.
[4]石亚飞,闫荟,孙世光,等.两种丹参类中药注射剂治疗冠心病心绞痛的系统评价及其药物经济学分析[J].中国循证医学杂志,2014,14(3):287-291.
[5]熊周勇,周燕弟.加味丹参饮联合西药治疗冠心病心绞痛心血瘀阻证的临床观察[J].光明中医,2017,32(18):2688-2690.
[6]金香兰.加味丹参饮联合西药治疗冠心病心绞痛心血瘀阻证35例疗效分析[J].中国实用医药,2016,11(25):181-182.
[7]毕颖斐,毛静远,王贤良,等.中医药防治冠心病临床优势及有关疗效评价的思考[J].中医杂志,2015,56(5):437-440.
[8]殷佳,宋彦奇,潘晔,等.基于临床文献探讨冠心病气阴两虚证动物模型的评价标准[J].中草药,2017,48(4):798-802.